Nabriva Therapeutics (NBRV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock NBRV vs. ALMS, MDWD, GNFT, ACRV, FULC, RAPT, TARA, PBYI, NBTX, and LYELShould you be buying Nabriva Therapeutics stock or one of its competitors? The main competitors of Nabriva Therapeutics include Alumis (ALMS), MediWound (MDWD), Genfit (GNFT), Acrivon Therapeutics (ACRV), Fulcrum Therapeutics (FULC), RAPT Therapeutics (RAPT), Protara Therapeutics (TARA), Puma Biotechnology (PBYI), Nanobiotix (NBTX), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. Nabriva Therapeutics vs. Alumis MediWound Genfit Acrivon Therapeutics Fulcrum Therapeutics RAPT Therapeutics Protara Therapeutics Puma Biotechnology Nanobiotix Lyell Immunopharma Alumis (NASDAQ:ALMS) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, community ranking, profitability, earnings and risk. Which has preferable valuation and earnings, ALMS or NBRV? Alumis has higher earnings, but lower revenue than Nabriva Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlumisN/AN/AN/AN/AN/ANabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/A Do analysts prefer ALMS or NBRV? Alumis presently has a consensus target price of $26.00, suggesting a potential upside of 381.48%. Given Alumis' stronger consensus rating and higher probable upside, analysts plainly believe Alumis is more favorable than Nabriva Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer ALMS or NBRV? In the previous week, Alumis had 30 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 31 mentions for Alumis and 1 mentions for Nabriva Therapeutics. Alumis' average media sentiment score of 0.45 beat Nabriva Therapeutics' score of 0.00 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 3 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nabriva Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in ALMS or NBRV? Nabriva Therapeutics received 373 more outperform votes than Alumis when rated by MarketBeat users. However, 100.00% of users gave Alumis an outperform vote while only 54.89% of users gave Nabriva Therapeutics an outperform vote. CompanyUnderperformOutperformAlumisOutperform Votes20100.00% Underperform VotesNo VotesNabriva TherapeuticsOutperform Votes39354.89% Underperform Votes32345.11% Do institutionals and insiders hold more shares of ALMS or NBRV? 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 1.6% of Nabriva Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is ALMS or NBRV more profitable? Alumis has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Alumis' return on equity of 0.00% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AlumisN/A N/A N/A Nabriva Therapeutics -148.11%-365.53%-135.81% SummaryAlumis beats Nabriva Therapeutics on 10 of the 14 factors compared between the two stocks. Remove Ads Get Nabriva Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBRV vs. The Competition Export to ExcelMetricNabriva TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.46M$6.87B$5.61B$7.68BDividend YieldN/A2.79%5.33%4.02%P/E Ratio0.007.3523.5018.55Price / SalesN/A208.36376.0088.66Price / CashN/A65.6738.1734.64Price / BookN/A6.256.814.11Net Income-$57.19M$142.34M$3.20B$247.18M Nabriva Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070ALMSAlumisN/A$3.78+0.8%$26.00+587.8%N/A$178.50MN/A0.00N/AAnalyst RevisionMDWDMediWound1.6112 of 5 stars$16.45+1.1%$31.33+90.5%+11.9%$177.55M$20.22M-5.6780GNFTGenfit2.0914 of 5 stars$3.53-2.8%$13.00+268.3%+1.8%$176.49M$76.06M0.00120Upcoming EarningsACRVAcrivon Therapeutics2.2829 of 5 stars$5.61+4.7%$23.67+321.9%-68.7%$174.67MN/A-2.0858Earnings ReportAnalyst RevisionFULCFulcrum Therapeutics1.7004 of 5 stars$3.21+1.9%$8.63+168.7%-68.1%$173.27M$80M-10.35100Gap DownRAPTRAPT Therapeutics3.789 of 5 stars$1.53+16.8%$5.29+245.5%-86.4%$172.93M$1.53M-0.5580Gap DownTARAProtara Therapeutics2.3707 of 5 stars$4.70+2.2%$22.50+378.7%+14.2%$172.81MN/A-1.6730Short Interest ↓Gap UpPBYIPuma Biotechnology4.3194 of 5 stars$3.47-1.1%$7.00+101.7%-40.8%$172.15M$230.47M7.23200Positive NewsNBTXNanobiotix2.6013 of 5 stars$3.62-0.1%$12.00+231.9%-44.2%$170.43M$36.22M0.00100LYELLyell Immunopharma3.7054 of 5 stars$0.56-3.3%$1.00+78.8%-75.7%$165.09M$61,000.00-0.71270Short Interest ↓Positive NewsGap Up Remove Ads Related Companies and Tools Related Companies ALMS Alternatives MDWD Alternatives GNFT Alternatives ACRV Alternatives FULC Alternatives RAPT Alternatives TARA Alternatives PBYI Alternatives NBTX Alternatives LYEL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBRV) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nabriva Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nabriva Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NBRV Stock Free NBRV Stock Alerts